ClinicalTrials.gg
Not yet recruitingNCT07948434Updated Nov 19, 2026

Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave

An interventional study of Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) and Treatment as Usual (TAU) in Stress, Anxiety and Depression, sponsored by University of Aarhus. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies in Depression by University of Aarhus — 3 open to participants now, 4 under way, none of them phase 3. Depression · University of Aarhus.

Planned enrollment
12th of 19
70 · median 88
Started
2027
the only one that year
No phase
19 of 23
3 open now
Registered
23rd of 23
by date

Among the 23 studies in Depression by University of Aarhus, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, and was the 23rd registered.

Depression

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 23 studies in Depression by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,099 Depression studies recruiting now, 474 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Depression by University of Aarhus, or all of them as a file.
02

Study summary

The investigators aim to evaluate the effectiveness of Focused Acceptance and Commitment Therapy combined with workplace involvement (FACT-WI) in reducing perceived stress, improving psychological well-being, and supporting return to work among employees on sick leave due to common mental disorders.

Read the detailed description

In the present study, participants will be randomly assigned to one of two groups, receiving either Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) or treatment as usual (TAU). FACT-WI will be delivered flexibly according to individual needs over a three-month period, with the possibility of involving the participant's immediate manager to support return to work.

  1. It is hypothesized that FACT-WI will be more effective than TAU in reducing perceived stress and improving quality of life over time.
  2. It is hypothesized that participants receiving FACT-WI will return to work more quickly than participants receiving TAU, including both part-time and full-time return to work.
  3. The feasibility and acceptability of FACT-WI will be evaluated.
  4. The number and duration of sessions received, as well as the extent and format of workplace involvement, will be explored.
  5. Managers' experiences of workplace involvement, including its perceived relevance, usefulness, barriers, facilitating factors, and suggestions for improvement, will be explored.
03

Conditions studied

  • Stress
  • Anxiety
  • Depression
  • Sickness Absence
  • Common Mental Disorders (CMD)

Browse trials for

Keywords

  • Return to Work
  • Focused Acceptance and Commitment Therapy (FACT)
  • Workplace Involvement
  • Occupational Mental Health
04

In context

Depression Reclassified

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

This study's planned enrollment of 70 is below the median of 81 across 7,083 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria are (i) age ≥ 18 years, (ii) currently being on part-time or full-time sick leave at the start of the study, (iii) symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9) questionnaire and/or symptoms of depression assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10) and/or symptoms of stress measured with the Perceived Stress Scale (PSS-10 ≥ 17), (iv) Danish language proficiency, (v) ability and willingness to give , (vi) access to either a smartphone, tablet, or computer with video camera. (vii) Be currently employed and anticipate to continue employment within the organizational setting. (viii)) have been employed in the current organization for a minimum of six months.

Exclusion criteria

Exclusion Criteria:

Exclusion criteria are: (i) currently receiving other psychotherapy for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization. (vi) being on sick leave for more than 4 months at the time of inclusion. (vii) a somatic or medical condition that is considered to prevent the participant from RTW. (viii) PTSD symptoms that re-quire treatment beyond the scope of the brief intervention. (ix) having an active Section 56 agreement under the Danish Sickness Benefits Act at the time of inclusion. In addition, potential participants must be clinically assessed as suitable for this brief intervention.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    FACT-WI

    Brief ACT-based intervention with optional workplace involvement

    Behavioral: Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI)

  • Other
    Treatment as Usal (TAU)

    Treatment as usual (TAU), including any support or services ordinarily available to employees on sick leave.

    Other: Treatment as Usual (TAU)

Interventions

  • BehavioralFocused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI)

    Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) is a brief, flexible intervention based on Acceptance and Commitment Therapy (ACT). The intervention aims to increase psychological flexibility, reduce psychological distress, and support return to work. Participants receive up to 300 minutes of online therapist contact over a period of three months. The intervention is tailored to individual needs and focuses on identifying psychological and work-related barriers, promoting values-based action, and developing strategies to support return to work. Workplace involvement is offered when relevant and may include written communication with the participant's immediate manager, verbal contact, or a joint meeting between the participant, manager, and therapist. The purpose is to address work-related barriers and facilitate a sustainable return to work. Workplace involvement is voluntary and requires the participant's consent.

  • OtherTreatment as Usual (TAU)

    Participants allocated to the control group will receive treatment as usual (TAU). They will have access to the usual healthcare and support services available to employees on sick leave, including relevant services provided by the municipality, workplace, or healthcare system.

07

What researchers measure

Primary outcomes

  1. Perceived stress

    Perceived Stress Scale-10 (PSS-10; Cohen \& Williamson, 1988). The scale consists of 10 items rated from 0 to 4, resulting in a total score ranging from 0 to 40. Higher scores indicate higher levels of perceived stress (i.e., a negative outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

  2. Quality of life (well-being)

    the World Health Organization-5 questionnaire (Bech, 1999; Topp et al., 2015; WHO-5). 5 items are rated on a scale from 0 to 5 with total scores ranging from 0 to 25. Higher scores are indicative of higher levels of life quality (i.e., a positive outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Secondary outcomes

  1. Time to Return to Work (RTW)

    Time to return to work, including both part-time and full-time return to work. Using administrative sickness absence records.

    Time frame: From baseline to 3 months (post-treatment) and 6 months (follow-up).

  2. Sickness Absence Percentage

    Percentage of scheduled working time lost due to sickness absence, based on administrative sickness absence records. Higher percentages indicate greater sickness absence (i.e., a negative outcome).

    Time frame: At 3 months (post-treatment) and 6 months (follow-up).

  3. Depressive symptoms

    Patient Health Questionnaire-9 (Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000; PHQ-9). 9 items are rated on a scale from 0 to 3, with a potential total range from 0 to 27. Larger scores mean more depressive symptoms (i.e., a negative outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

  4. Anxiety symptoms

    General Anxiety Disorder-7 (Spitzer et al., 2006; GAD-7). 7 items are rated on scale from 0 to 7 with total scores ranging from 0 to 21. Higher scores are indicative of more symptoms of GAD (i.e., a negative outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

  5. Valued Living

    Valuing Questionnaire (Smout et al., 2014; VQ). 10 items are rated on a scale from 0 to 6 with total scores ranging from 0 to 60. Higher scores a indicative of actions/life being guided by personally held values (i.e., a positive outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

  6. Harm/negative effects

    The Negative Effects Questionnaire (Rozental et al., 2019; NEQ). 32 questions are answered yes/no. If yes, items are rated on a scale from 1 to 5 and participants are asked if the negative effect experience can be attrubuted to the treatment or other crcumstances. Total scores range from 32 to 160 with higher scores indicating more negative effects (i.e., a negative outcome).

    Time frame: Measured once at post-treatment (3 months), in the intervention group only.

  7. Experiental Avoidance

    Brief Experiential Avoidance Questionnaire (BEAQ; Gámez et al., 2014). The questionnaire consists of 15 items rated from 1 to 6, resulting in a total score ranging from 15 to 90. Higher scores indicate greater experiential avoidance (i.e., a negative outcome).

    Time frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

  8. Client Satisfaction Questionnaire

    Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979). The questionnaire consists of eight items rated from 1 to 4, resulting in a total score ranging from 8 to 32. Higher scores indicate greater satisfaction with the intervention. The questionnaire will be administered to participants in the FACT-WI group only.

    Time frame: Measured once at 3 months (follow-up), in the intervention group only.

08

Study locations

No study locations are listed for this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 3,483 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 19 months is close to that.

Counting every sponsor, half of 3,581 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 19, 2026
StartEst.
Jan 25, 2027
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948434
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 25, 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Vita Ligaya Ponce Dalgaard, PhD, MSc
Contact
ligayadalgaard@psy.au.dk
004587165805
Astrid Olesen Liboriussen, MSc
Contact
astridol@psy.au.dk
004553356030

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion